World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
45084
World Ranking
14832
National Ranking
7496

Shirish M. Gadgeel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Shirish M. Gadgeel sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 779 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Shirish M. Gadgeel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Shirish M. Gadgeel sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Shirish M. Gadgeel is affiliated with the University of Michigan-Ann Arbor in the United States. Their research primarily focuses on medicine, with a strong emphasis on oncology and pulmonary and respiratory medicine. Additional subfields of study include molecular biology, cancer research, and radiology, nuclear medicine, and imaging.

The scientist's research covers several main topics, notably lung cancer treatments and mutations, cancer immunotherapy and biomarkers, lung cancer research studies, cancer genomics and diagnostics, lung cancer diagnosis and treatment, colorectal cancer treatments and studies, and HER2/EGFR in cancer research.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Clinical Lung Cancer
  • Annals of Oncology

Notable recent papers authored by Shirish M. Gadgeel include:

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer (2020, Journal of Clinical Oncology)
  • Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation (2022, New England Journal of Medicine, authored by Pasi A. Jänne)
  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020, Annals of Oncology, authored by Tony Mok)
  • Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study (2023, Journal of Clinical Oncology, authored by Marina Chiara Garassino)
  • Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study (2021, The Lancet Oncology, authored by Justin F. Gainor)

The scientist has collaborated extensively with several frequent co-authors, including:

  • Enriqueta Felip
  • Alexander I. Spira
  • Balázs Halmos
  • Sai-Hong Ignatius Ou
  • Tony Mok

In addition to articles, Shirish M. Gadgeel has contributed to book publications, including a title published by Cambridge University Press in 2023 called Targeting Oncogenic Driver Mutations in Lung Cancer.

Best Publications

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study

    Shirish M. Gadgeel;Leena Gandhi;Gregory J. Riely;Alberto A. Chiappori

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Benjamin J. Solomon;Benjamin Besse;Benjamin Besse;Todd M. Bauer;Enriqueta Felip

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Alice T Shaw;Leena Gandhi;Shirish Gadgeel;Gregory J Riely

  • Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

    Patricia M. LoRusso;Alex A. Adjei;Mary Varterasian;Shirish Gadgeel

  • Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.

    T. Mok;D.R. Camidge;S.M. Gadgeel;R. Rosell

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean Charles Soria;Enriqueta Felip;Manuel Cobo;Shun Lu

  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    D. Ross Camidge;Rafal Dziadziuszko;Solange Peters;Tony Mok

  • The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions

    Louis A. Penner;John F. Dovidio;Richard Gonzalez;Terrance L. Albrecht

  • Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer

    John V. Heymach;Bruce E. Johnson;Diane Prager;Edit Csada

  • Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

    Justin F. Gainor;Giuseppe Curigliano;Dong Wan Kim;Dae Ho Lee

  • A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

    Eric B. Haura;Alejandro D. Ricart;Timothy G. Larson;Philip J. Stella

  • Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer

    J. Gainor;L. Dardaei;S. Yoda;L. Friboulet

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean-Charles Soria;Soria Jean-Charles;Enriqueta Felip;Felip Enriqueta

Frequent Co-Authors

Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
D. Ross Camidge
D. Ross Camidge University of Colorado Anschutz Medical Campus
Alice T. Shaw
Alice T. Shaw Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Ann G. Schwartz
Ann G. Schwartz Wayne State University
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Edward B. Garon
Edward B. Garon University of California, Los Angeles
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to various online degree options and related healthcare fields. Many students consider healthcare administration programs to understand the business and organizational side of healthcare. These programs equip graduates for leadership roles and can be completed online, offering valuable flexibility.

For registered nurses seeking advancement, numerous rn to fnp programs allow working nurses to transition smoothly into Family Nurse Practitioner roles. These bridge programs can also be pursued online, supporting career growth while balancing current job responsibilities.

Those interested in preventative care and wellness may explore the best online nutrition degree programs. These degrees provide foundational knowledge in nutrition science and can lead to diverse opportunities in clinical, community, or corporate settings.

When researching graduate studies, ensure your program holds recognized accreditation such as cahme accreditation, which assures high-quality standards for health administration master’s degrees. Choosing accredited online programs can enhance your credentials and expand your professional options within the healthcare sector.

Best Scientists Citing Shirish M. Gadgeel

Trending Scientists

Recently Published Articles